regulations

warning: Creating default object from empty value in /home/hemporg/public_html/news/modules/taxonomy/taxonomy.pages.inc on line 34.

Arizona: Cannabis Legal Expert Earns Partnership At Top Law Firm

LauraBianchi[RoseLawGroup].jpg

The Rose Law Group of Arizona has named marijuana legal expert Laura Bianchi a partner in the firm. According to the firm, "the promotion was based on her demonstrated ability to navigate increasingly complex regulations as well as her pioneering legal efforts in the multi-billion dollar cannabis industry."

Along with her partner promotion, she will continue as director of the Business/Corporate Transactions and Estate Planning and Asset Protection departments.

Since Arizona’s medical marijuana legalization in 2010, Bianchi has been at the forefront, helping to transition the industry from illegality to legitimacy. As an integral part of Rose Law Group’s Medical Marijuana practice, Bianchi and her colleagues configured and instituted legal precedents where no prevailing template existed.

Bianchi’s innovative work and expertise in business transactions and administrative law have allowed her to establish a diverse and loyal client base throughout Arizona and across the country. Her continued success has lead to national recognition. In 2016, she was named a Rising Star by Super Lawyers, a rating service that selects and honors outstanding lawyers from across all 50 states.

Ohio: Patients Still Lose Under Latest Medical Marijuana Plan From Legislature

OhioansForMedicalMarijuana2016[OhioansForMMJ.org].jpg

As state lawmakers unveiled a revised version of HB 523, Ohioans for Medical Marijuana on Wednesday released a statement expressing disappointment with the narrow and restrictive substitute bill.

“The latest version fails to address the critical flaws in the bill that significantly restrict patient access,” said Aaron Marshall, spokesman for Ohioans for Medical Marijuana. “Very few doctors will be willing to enter into a system that doesn’t trust them to make decisions that are in the best interest of their patients and ties their hands with regulatory red tape. With so few doctors participating, patients will not have access to the medicine they need.”

Provisions in the revised legislation require doctors to recommend specific THC levels and strains of medical marijuana for patients. “These kinds of provisions risk putting doctors at odds with federal law, and have significantly hindered the two-year-old medical marijuana program in New York,” said Marshall.

U.S.: Thursday Webinar To Address Quality Control In Medical Marijuana

MarijuanaScience[Bloomberg].jpg

By Steve Elliott
Hemp News

A Thursday press briefing via Webinar will address the need for better quality control in medical marijuana products.

The briefing, hosted by RTI International, will address the public health risks arising in this unregulated market due to factors such as:

• Product types and formulations that vary from state to state, store to store, even product to product;
• Inaccurate product labeling and marketing claims;
• Limited testing of medical marijuana products for safety and efficacy; and
• Lack of professional guidelines and governmental regulations. This places the burden on the consumers and providers to be aware of the above factors and how they affect dosing and ultimately, safety.

This briefing comes at a time when the number of medical marijuana users is on the rise in the U.S. and even presidential candidates on the campaign trail are calling for more research.

Marijuana itself, of course, is as safe as it ever was. But as big corporate money and big corporate mass production methods have come to the medicinal cannabis world, the mom-and-pop atmosphere of trust and safety which had distinguished the industry from the rest of the cut-throat economy is fading away. Production is increased by using chemical fertilizers and harsh pesticides, and those who are focused only on profit and not on healing are looking only at the bottom line.

Colorado: Cannabis Industry Reaches Nearly $1 Billion In 2015

CannabisBusinessAlliance(CBA)[logo].jpg

Cannabis Business Alliance applauds Colorado’s impressive growth while noting regulatory challenges ahead

Colorado has released the cannabis industry sales report for 2015, with total sales reaching more than $996 million, an increase of more than 42 percent over the previous year.

The Cannabis Business Alliance (CBA) noted this impressive industry growth even as many of its members prepare for more regulatory challenges ahead.

“With greater growth and continuation of operators entering the industry, Cannabis Business Alliance members and Colorado operators have continually set the standard of the maturing industry nationwide, impressively thriving amidst increasing regulation, including stamping, equivalency, and pest management,” said Mark Slaugh, CBA Board member and iComply CEO.

“Amidst these regulatory hurdles, CBA and its members continue to be committed to protecting the health, safety and welfare of the public," Slaugh said. "We are especially focused in protecting our adolescents and youth, by encouraging and actively supporting adult-use education, responsible parenting, and pragmatic and sensible regulations.”

During the second full year of recreational cannabis sales, Colorado retailers sold more than $587 million of recreational cannabis and more than $408 million of medical cannabis. In 2014, the total sales of medical and recreational cannabis in Colorado added up to roughly $700 million, making this year’s growth an impressive 42 percent.

Colorado: Denver Attorney Named To Boulder Cannabis Advisory Board

RobertHoban.jpg

Robert Hoban, the managing partner of the Denver law firm Hoban and Feola LLC which specializes in the cannabis industry, has been named as a member of the newly-formed Boulder City Council’s marijuana advisory panel.

Hoban was chosen as the only attorney on the 11-person panel whose mandate is to provide recommendations on making the city’s cannabis regulations more comprehensive and easily implemented.

The panel will review sections of Boulder's cannabis code that may need revision in order to make them more workable and coordinated with the state’s cannabis regulations. Among the issues that the panel may consider will be regulations related to packaging, transportation, advertising, chain of supply, and security.

“The advisory panel serves as an important source of information from key segments of the medical cannabis industry, the community and the general public,” Hoban said.

“The city of Boulder and Colorado have been on the leading edge of passing and enacting legislation in the cannabis industry and the Boulder advisory panel is an important link to make sure effective public policy is developed and enacted at the community level," Hoban said. "The city of Boulder is to be commended for establishing this panel so all interested parties can be confident that their various concerns are being heard.”

The group is advisory, and any ordinance changes the panel recommends would require the approval of the Boulder City Council. Panel meetings will be open to the public and their input is invited, according to city officials.

Syndicate content